Ermer, Theresa http://orcid.org/0000-0001-8483-5758
Nazzal, Lama
Tio, Maria Clarissa
Waikar, Sushrut http://orcid.org/0000-0003-4004-326X
Aronson, Peter S. http://orcid.org/0000-0002-1860-2419
Knauf, Felix http://orcid.org/0000-0001-5762-1404
Article History
Accepted: 27 September 2022
First Online: 3 November 2022
Competing interests
: F.K. reports personal fees from Allena, Oxthera, Sanofi, Fresenius Medical Care, Alnylam Pharmaceuticals, Advicenne, Medice and Zai, and grant support from Alnylam and Dicerna Pharmaceuticals. S.W. reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, GSK, Allena Pharmaceuticals, Mass Medical International, Barron and Budd (versus Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (also known as Baim Institute for Clinical Research), Oxidien, Sironax, Metro Biotechnology, Biomarin, Bain and Regeneron. L.N. reports personal fees from Oxthera, Dicerna, Federation Bio, Allena, Novome and Synlogic. All other authors declare no competing interests.